THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 92 filers reported holding THERAVANCE BIOPHARMA INC in Q2 2014. The put-call ratio across all filers is 0.66 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $1,045,000 | +11.9% | 103,049 | 0.0% | 0.01% | +16.7% |
| Q2 2022 | $934,000 | -63.9% | 103,049 | -61.9% | 0.01% | -57.1% |
| Q1 2022 | $2,588,000 | -9.7% | 270,691 | +4.4% | 0.01% | -6.7% |
| Q4 2021 | $2,866,000 | +120.5% | 259,395 | +47.7% | 0.02% | +114.3% |
| Q3 2021 | $1,300,000 | -50.0% | 175,674 | -2.0% | 0.01% | -50.0% |
| Q2 2021 | $2,602,000 | -31.9% | 179,200 | -4.2% | 0.01% | -33.3% |
| Q1 2021 | $3,819,000 | +16.2% | 187,115 | +1.2% | 0.02% | +10.5% |
| Q4 2020 | $3,287,000 | +134.1% | 184,987 | +94.8% | 0.02% | +111.1% |
| Q3 2020 | $1,404,000 | -29.5% | 94,961 | +0.1% | 0.01% | -30.8% |
| Q2 2020 | $1,991,000 | +2704.2% | 94,855 | +2949.0% | 0.01% | – |
| Q1 2019 | $71,000 | -11.2% | 3,111 | 0.0% | 0.00% | – |
| Q4 2018 | $80,000 | -21.6% | 3,111 | 0.0% | 0.00% | – |
| Q3 2018 | $102,000 | +45.7% | 3,111 | 0.0% | 0.00% | – |
| Q2 2018 | $70,000 | -6.7% | 3,111 | 0.0% | 0.00% | – |
| Q1 2018 | $75,000 | -13.8% | 3,111 | 0.0% | 0.00% | – |
| Q4 2017 | $87,000 | -18.7% | 3,111 | 0.0% | 0.00% | – |
| Q3 2017 | $107,000 | -96.3% | 3,111 | -95.7% | 0.00% | -100.0% |
| Q2 2017 | $2,862,000 | +9.6% | 71,833 | +1.3% | 0.01% | +9.1% |
| Q1 2017 | $2,611,000 | +12.9% | 70,925 | -2.3% | 0.01% | 0.0% |
| Q4 2016 | $2,313,000 | -61.5% | 72,567 | -56.2% | 0.01% | -62.1% |
| Q3 2016 | $6,001,000 | +24.7% | 165,581 | -21.9% | 0.03% | +20.8% |
| Q2 2016 | $4,813,000 | +43.9% | 212,115 | +19.2% | 0.02% | +41.2% |
| Q1 2016 | $3,345,000 | +93.5% | 177,912 | +68.6% | 0.02% | +88.9% |
| Q4 2015 | $1,729,000 | +126.9% | 105,494 | +52.2% | 0.01% | +125.0% |
| Q3 2015 | $762,000 | -5.6% | 69,306 | +11.8% | 0.00% | 0.0% |
| Q2 2015 | $807,000 | +8.9% | 62,008 | +45.2% | 0.00% | 0.0% |
| Q1 2015 | $741,000 | +72.3% | 42,696 | +48.2% | 0.00% | +100.0% |
| Q4 2014 | $430,000 | -49.8% | 28,808 | -22.4% | 0.00% | -50.0% |
| Q3 2014 | $856,000 | -27.9% | 37,127 | -0.4% | 0.00% | -33.3% |
| Q2 2014 | $1,188,000 | – | 37,260 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Madison Avenue Partners, LP | 7,269,584 | $69,497,223,000 | 12.98% |
| Newtyn Management, LLC | 1,375,000 | $13,145,000 | 3.15% |
| Chescapmanager LLC | 1,166,574 | $11,152,000 | 1.51% |
| Baupost Group | 13,643,333 | $130,430,000 | 1.40% |
| Weiss Asset Management LP | 5,412,487 | $51,743,000 | 1.07% |
| CM Management, LLC | 120,000 | $1,147,000 | 0.96% |
| Orbimed Advisors | 3,254,713 | $31,115,000 | 0.50% |
| King Wealth Management Group | 122,000 | $1,166,000 | 0.23% |
| Woodline Partners LP | 1,326,653 | $12,683,000 | 0.21% |
| PDT Partners, LLC | 192,701 | $1,842,000 | 0.16% |